Diverse responses to vascular disrupting agent combretastatin A4 phosphate: A comparative study in rats with hepatic and subcutaneous tumor allografts using MRI biomarkers, microangiography, and histopathology

Translational Oncology

Volumn 6, Issue 1, 2013, Pages 42-50

  Li, Junjie ^a,b   Chen, Feng ^a,b   Feng, Yuanbo ^a,b   Cona, Marlein Miranda ^a,b   Yu, Jie ^a   Verbruggen, Alfons ^c   Zhang, Jian ^d   Oyen, Raymond ^a   Ni, Yicheng ^a,b,d  

^a DEPARTMENT OF IMAGING AND PATHOLOGY   (Belgium)

^b KU Leuven   (Belgium)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d Laboratory of Translational Medicine   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BARIUM SULFATE; COMBRETASTATIN A4 PHOSPHATE; GADOTERATE MEGLUMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIFFUSION COEFFICIENT; DRUG RESPONSE; HISTOPATHOLOGY; LIVER TUMOR; MALE; MICROANGIOGRAPHY; MORPHOMETRICS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; RAT; SUBCUTANEOUS TISSUE TUMOR; TUMOR GROWTH; TUMOR NECROSIS; TUMOR VOLUME;

EID: 84874715009     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.12367     Document Type: Article

References (50)

1. Li J, Chen F, Cona MM, Feng Y, Himmelreich U, Oyen R, Verbruggen A, and Ni Y (2012). A review on various targeted anticancer therapies. Target Oncol 7, 69-85.
2. Schnitzer JE (1998). Vascular targeting as a strategy for cancer therapy. N Engl J Med 339, 472-474.
3. Arap W, Pasqualini R, and Ruoslahti E (1998). Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279, 377-380.
4. Ching LM, Zwain S, and Baguley BC (2004). Relationship between tumour endothelial cell apoptosis and tumour blood flow shutdown following treatment with the antivascular agent DMXAA in mice. Br J Cancer 90, 906-910.
5. Seshadri M, Spernyak JA, Maiery PG, Cheney RT, Mazurchuk R, and Bellnier DA (2007). Visualizing the acute effects of vascular-targeted therapy in vivo using intravital microscopy and magnetic resonance imaging: correlation with endothelial apoptosis, cytokine induction, and treatment outcome. Neoplasia 9, 128-135.
6. McPhail LD, McIntyre DJ, Ludwig C, Kestell P, Griffiths JR, Kelland LR, and Robinson SP (2006). Rat tumor response to the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid as measured by dynamic contrast-enhanced magnetic resonance imaging, plasma 5-hydroxyindoleacetic acid levels, and tumor necrosis. Neoplasia 8, 199-206.
7. Ching L, Goldsmith D, Joseph WR, Korner H, Sedgwick JD, and Baguley BC (1999). Induction of intratumoral tumor necrosis factor (TNF) synthesis and hemorrhagic necrosis by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF knockout mice. Cancer Res 59, 3304-3307.
8. Rustin GJ, GalbraithSM, AndersonH, Stratford M, Folkes LK, Sena L, Gumbrell L, and Price PM (2003). Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J Clin Oncol 21, 2815-2822.
9. Tozer GM, Kanthou C, and Baguley BC (2005). Disrupting tumour blood vessels. Nat Rev Cancer 5, 423-435.
10. Rustin MZAG (2010). The clinical development of tubulin binding vascular disrupting agents. In Vascular Disruptive Agents for the Treatment of Cancer. TMeyer (Ed.). Springer. pp. 183-216: Part 3.
11. Li J, Raymond O, Verbruggen A, and Ni Y (in press). Small molecule sequential dual-targeting theragnostic strategy (SMSDTTS): from preclinical experiments towards possible clinical anticancer applications. J Cancer.
12. Cooney MM, Ortiz J, Bukowski RM, and Remick SC (2005). Novel vascular targeting/disrupting agents: combretastatin A4 phosphate and related compounds. Curr Oncol Rep 7, 90-95.
13. Wang H, Sun X, Chen F, De Keyzer F, Yu J, Landuyt W, Vandecaveye V, Peeters R, Bosmans H, Hermans R, et al. (2009). Treatment of rodent liver tumor with combretastatin a4 phosphate: noninvasive therapeutic evaluation using multiparametric magnetic resonance imaging in correlation with microangiography and histology. Invest Radiol 44, 44-53.
14. Anderson HL, Yap JT, Miller MP, Robbins A, Jones T, and Price PM (2003). Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate. J Clin Oncol 21, 2823-2830.
15. Zweifel M, Jayson GC, Reed NS, Osborne R, Hassan B, Ledermann J, Shreeves G, Poupard L, Lu SP, Balkissoon J, et al. (2011). Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer. Ann Oncol 22, 2036-2041.
16. West CM and Price P (2004). Combretastatin A4 phosphate. Anticancer Drugs 15, 179-187.
17. Tozer GM, Prise VE, Wilson J, Cemazar M, Shan S, Dewhirst MW, Barber PR, Vojnovic B, and Chaplin DJ (2001). Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. Cancer Res 61, 6413-6422.
18. Tozer GM, Prise VE, Lewis G, Xie S, Wilson I, and Hill SA (2009). Nitric oxide synthase inhibition enhances the tumor vascular-damaging effects of combretastatin a-4 3-o-phosphate at clinically relevant doses. Clin Cancer Res 15, 3781-3790.
19. Salmon BA and Siemann DW (2007). Characterizing the tumor response to treatment with combretastatin A4 phosphate. Int J Radiat Oncol Biol Phys 68, 211-217.
20. Li J, Sun Z, Zhang J, Shao H, Miranda Cona M, Wang H, Marysael T, Chen F, Prinsen K, Zhou L, et al. (2011). A dual-targeting anticancer approach: soil and seed principle. Radiology 260, 799-807.
21. Rustin GJ, Shreeves G, Nathan PD, Gaya A, Ganesan TS, Wang D, Boxall J, Poupard L, Chaplin DJ, Stratford MR, et al. (2010). A phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer. Br J Cancer 102, 1355-1360.
22. Mitrus I, Sochanik A, Cichon T, and Szala S (2009). Combination of combretastatin A4 phosphate and doxorubicin-containing liposomes affects growth of B16-F10 tumors. Acta Biochim Pol 56, 161-165.
23. Bilenker JH, Flaherty KT, Rosen M, Davis L, Gallagher M, Stevenson JP, Sun W, Vaughn D, Giantonio B, Zimmer R, et al. (2005). Phase I trial of combretastatin a-4 phosphate with carboplatin. Clin Cancer Res 11, 1527-1533.
24. Chen F, Feng Y, Zheng K, De Keyzer F, Li J, Feng Y, Miranda CM, Wang H, Jiang Y, Yu J, et al. (2012). Enhanced antitumor efficacy of a vascular disrupting agent combined with an antiangiogenic in a rat liver tumor model evaluated by multiparametric MRI. PLoS One 7, e41140.
25. Tozer GM, Kanthou C, Lewis G, Prise VE, Vojnovic B, and Hill SA (2008). Tumour vascular disrupting agents: combating treatment resistance. Br J Radiol 81, S12-S20.
26. Prise VE, Honess DJ, Stratford MR, Wilson J, and Tozer GM (2002). The vascular response of tumor and normal tissues in the rat to the vascular targeting agent, combretastatin A-4-phosphate, at clinically relevant doses. Int J Oncol 21, 717-726.
27. Gridelli C, Rossi A, Maione P, Rossi E, Castaldo V, Sacco PC, and Colantuoni G (2009). Vascular disrupting agents: a novel mechanism of action in the battle against non-small cell lung cancer. Oncologist 14, 612-620.
28. Siemann DW and Horsman MR (2009). Vascular targeted therapies in oncology. Cell Tissue Res 335, 241-248.
29. Wang H, Cona MM, Chen F, Yu J, Feng Y, Li J, Keyzer FD, Marchal G, and Ni Y (2012). Comparison of two vascular-disrupting agents at a clinically relevant dose in rodent liver tumors with multiparametric magnetic resonance imaging biomarkers. Anticancer Drugs 23, 12-21.
30. Wang H, Marchal G, and Ni Y (2011). Multiparametric MRI biomarkers for measuring vascular disrupting effect on cancer. World J Radiol 3, 1-16.
31. Chen F, De Keyzer F, and Ni Y (2011). Cancer models-multiparametric applications of clinical MRI in rodent hepatic tumor model. Methods Mol Biol 771, 489-507.
32. Evelhoch JL, LoRusso PM, He Z, DelProposto Z, Polin L, Corbett TH, Langmuir P, Wheeler C, Stone A, Leadbetter J, et al. (2004). Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126. Clin Cancer Res 10, 3650-3657.
33. Vogel-Claussen J, Gimi B, Artemov D, and Bhujwalla ZM (2007). Diffusionweighted and macromolecular contrast enhanced MRI of tumor response to antivascular therapy with ZD6126. Cancer Biol Ther 6, 1469-1475.
34. Thoeny HC, De Keyzer F, Vandecaveye V, Chen F, Sun X, Bosmans H, Hermans R, Verbeken EK, Boesch C, Marchal G, et al. (2005). Effect of vascular targeting agent in rat tumor model: dynamic contrast-enhanced versus diffusion-weighted MR imaging. Radiology 237, 492-499.
35. Chen F, Sun X, De Keyzer F, Yu J, Peeters R, Coudyzer W, Vandecaveye V, Landuyt W, Bosmans H, Van Hecke P, et al. (2006). Liver tumor model with implanted rhabdomyosarcoma in rats: MR imaging, microangiography, and histopathologic analysis. Radiology 239, 554-562.
36. Schwartz M (1961). A biomathematical approach to clinical tumor growth. Cancer 14, 1272-1294.
37. Sun X, Wang H, Chen F, De Keyzer F, Yu J, Jiang Y, Feng Y, Li J, Marchal G, and Ni Y (2009). Diffusion-weightedMRI of hepatic tumor in rats: comparison between in vivo and postmortem imaging acquisitions. J Magn Reson Imaging 29, 621-628.
38. Wang H, Li J, Chen F, De Keyzer F, Yu J, Feng Y, Nuyts J, Marchal G, and Ni Y (2010). Morphological, functional and metabolic imaging biomarkers: assessment of vascular-disrupting effect on rodent liver tumours. Eur Radiol 20, 2013-2026.
39. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, et al. (2000). New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92, 205-216.
40. Husband JE, Schwartz LH, Spencer J, Ollivier L, King DM, Johnson R, and Reznek R (2004). Evaluation of the response to treatment of solid tumours-a consensus statement of the International Cancer Imaging Society. Br J Cancer 90, 2256-2260.
41. Ollivier L, Leclere J, Thiesse P, Di Stefano D, and Vincent C (2007). Measurement of tumour response to cancer treatment: morphologic imaging role. Bull Cancer 94, 171-177.
42. Padhani AR and Miles KA (2010). Multiparametric imaging of tumor response to therapy. Radiology 256, 348-364.
43. Tozer GM (2003). Measuring tumour vascular response to antivascular and antiangiogenic drugs. Br J Radiol 76, S23-S35.
44. Colvin DC, Jourquin J, Xu J, Does MD, Estrada L, and Gore JC (2011). Effects of intracellular organelles on the apparent diffusion coefficient of water molecules in cultured human embryonic kidney cells. Magn Reson Med 65, 796-801.
45. Wu X, Wang H, Chen F, Jin L, Li J, Feng Y, DeKeyzer F, Yu J, Marchal G, and Ni Y (2009). Rat model of reperfused partial liver infarction: characterization with multiparametric magnetic resonance imaging, microangiography, and histomorphology. Acta Radiol 50, 276-287.
46. Ni Y, Marchal G, van Damme B, van Hecke P, Michiels J, Zhang X, Yu J, and Baert AL (1992). Magnetic resonance imaging, microangiography, and histology in a rat model of primary liver cancer. Invest Radiol 27, 689-697.
47. Thoeny HC, De Keyzer F, Chen F, Ni Y, Landuyt W, Verbeken EK, Bosmans H, Marchal G, and Hermans R (2005). Diffusion-weighted MR imaging in monitoring the effect of a vascular targeting agent on rhabdomyosarcoma in rats. Radiology 234, 756-764.
48. Wang ES, Pili R, and Seshadri M (2012). Modulation of chemotherapeutic efficacy by vascular disrupting agents: optimizing the sequence and schedule. J Clin Oncol 30, 760-761.
49. Fukumura D, Yuan F, Monsky WL, Chen Y, and Jain RK (1997). Effect of host microenvironment on the microcirculation of human colon adenocarcinoma. Am J Pathol 151, 679-688.
50. Ohta S, Lai EW, Morris JC, Pang AL, Watanabe M, Yazawa H, Zhang R, Green JE, Chan WY, Sirajuddin P, et al. (2008). Metastasis-associated gene expression profile of liver and subcutaneous lesions derived from mouse pheochromocytoma cells. Mol Carcinog 47, 245-251.